Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 50632-53-6 | MDL No. : | MFCD00012599 |
Formula : | C3H10ClNO | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | BYXUIKZQGOPKFR-UHFFFAOYSA-N |
M.W : | 111.57 | Pubchem ID : | 170873 |
Synonyms : |
|
Num. heavy atoms : | 6 |
Num. arom. heavy atoms : | 0 |
Fraction Csp3 : | 1.0 |
Num. rotatable bonds : | 1 |
Num. H-bond acceptors : | 2.0 |
Num. H-bond donors : | 2.0 |
Molar Refractivity : | 27.03 |
TPSA : | 32.26 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.33 cm/s |
Log Po/w (iLOGP) : | 0.0 |
Log Po/w (XLOGP3) : | 0.91 |
Log Po/w (WLOGP) : | 1.18 |
Log Po/w (MLOGP) : | 0.63 |
Log Po/w (SILICOS-IT) : | -0.71 |
Consensus Log Po/w : | 0.4 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 2.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -1.04 |
Solubility : | 10.2 mg/ml ; 0.0914 mol/l |
Class : | Very soluble |
Log S (Ali) : | -1.17 |
Solubility : | 7.49 mg/ml ; 0.0671 mol/l |
Class : | Very soluble |
Log S (SILICOS-IT) : | -0.05 |
Solubility : | 99.9 mg/ml ; 0.895 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 1.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.33 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With hydrogenchloride; In tetrahydrofuran; pyridine; dichloromethane; | EXAMPLE 3 2-(6,11-Dihydro-11-oxodibenz[b,e]oxepin-2-yl)-N-hydroxy-N-(1-methylethyl)acetamide To a flask was added 10.0 g of <strong>[50632-53-6]N-<strong>[50632-53-6]isopropylhydroxylamine hydrochloride</strong></strong> in 400 ml of dry pyridine. The mixture was stirred to afford a solution, chilled with an ice bath and treated dropwise over several minutes with a solution of 5.72 g of 2-(6,11-dihydro-11-oxodibenz[b,e]oxepin-2-yl)acetyl chloride in 200 ml of dry tetrahydrofuran. The solution was stirred for 24 hours and was allowed to equilibrate to room temperature. The resulting cloudy suspension was condensed to an oil via rotary evaporation and was transferred to a separatory funnel. The product was partitioned against 500 ml of methylene chloride and a sufficient amount (500 ml) of 10% HCl to acidify the aqueous phase below pH 1. The dried (Na2 SO4) organic phase was filtered and concentrated to an oil using rotary evaporation. Thin layer analysis indicated a mixture, which was separated via HPLC to give 3.92 g of pure material. Recrystallization from acetone afforded 2-(6,11-dihydro-11-oxodibenz[b,e]oxepin-2-yl)-N-hydroxy-N-(1-methylethyl)acetamide, m.p. 144-145 C. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Example 51 N-Isopropyl-C-(4-diethylsulfamoylphenyl)nitrone (51) The title compound was prepared according to the procedure described in Example 23, starting from <strong>[50632-53-6]N-<strong>[50632-53-6]isopropylhydroxylamine hydrochloride</strong></strong> and 4-(diethylsulfamoyl) benzaldehyde MS: m/z 299 (MH+). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Example 55 N-Isopropyl-C-[4-(methyl-phenyl-sulfamoyl)phenyl]nitrone (55) The title compound was prepared according to the procedure described in Example 23, starting from <strong>[50632-53-6]N-<strong>[50632-53-6]isopropylhydroxylamine hydrochloride</strong></strong> and 4-(methyl-phenyl-sulfamoyl) benzaldehyde MS: m/z 333 (MH+). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Example 59 N-Isopropyl-C-[4-(tert-butylsulfamoyl)phenyl]nitrone (59) The title compound was prepared according to the procedure described in Example 23, starting from <strong>[50632-53-6]N-<strong>[50632-53-6]isopropylhydroxylamine hydrochloride</strong></strong> and 4-(tert-butylsulfamoyl) benzaldehyde MS: m/z 299 (MH+). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
77% | With sodium hydrogencarbonate; In tetrahydrofuran; at 20℃; for 3h; | Example 4; R (-)-2- [ (4'-trifluoromethanesulfonyloxy) phenyl] -N-isopropoxy propionamide; To a suspension of <strong>[50632-53-6]N-<strong>[50632-53-6]isopropylhydroxylamine hydrochloride</strong></strong> (0.14 g, 1.67 mmol) and NaHCO3 (0.19 g, 3.34 mmol) in anhydrous THF (5 mL), R (-)-2- (4'- trifluoromethanesulfonyloxyphenyl) propionyl chloride, prepared starting from the corresponding acid (0.5 g, 1.67 mmol) as described in the example 3, is added and the solution left stirring at room temperature for 3 h. After solvent evaporation the crude is diluted with CH2C12 (10 mL), washed with water (2 x 10 mL), dried on Na2SO4 and evaporated under reduced pressure to give an oily residue. The crude is purified by treatment with n-hexane and the formed precipitate, after filtration, affords the pure R (-)- 2- [ (4'-trifluoromethanesulfonyloxy) phenyl]-N-isopropoxy propionamide as white powder (0.45 g, 1.28 mmol) (yield 77%). Me =-24 (c=0.5 ; CH30H). 1H-NMR (CDC13): 8 8.15 (bs, 1H, CONH); 7.45 (d, 2H, J=7Hz); 7.20 (d, 2H, J=7Hz) ; 3.65 (m, 1H); 3.50 (q, 1H, J=7Hz); 1.55 (d, 3H, J=7Hz); 1.2 (d, 6H, J=3Hz). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
(A) 5-Fluoro-2-methyl-3-(N-2-propyl-N-hydroxy)-indenylacetamide is obtained from 5-fluoro-2-methylindenyl-3-acetyl chloride (Example 1, Step E) using the procedure of Example 3 1, Part A and replacing N-benzylhydroxylamine hydrochloride with N-2-propyl hydroxylamine hydrochloride. | ||
(A) 5-Fluoro-2-methyl-3-(N-2-propyl-N-hydroxy)-indenylacetamide is obtained from 5-fluoro-2-methylindenyl-3-acetyl chloride (Example 1, Step E) using the procedure of Example 31, Part A and replacing N-benzylhydroxylamine hydrochloride with N-2-propyl hydroxylamine hydrochloride. | ||
(A) 5-Fluoro-2-methyl-3-(N-2-propyl-N-hydroxy)-indenylacetamide is obtained from 5-fluoro-2-methylindenyl-3-acetyl chloride (Example 1, Step E) using the procedure of Example 31, Part A and replacing N-benzylhydroxylamine hydrochloride with N-2-propyl hydroxylamine hydrochloride. |
(A) 5-Fluoro-2-methyl-3-(N-2-propyl-N-hydroxy)-indenylacetamide is obtained from 5-fluoro-2-methylindenyl-3-acetyl chloride (Example 1, Step E) using the procedure of Example 31, Part A and replacing N-benzylhydroxylamine hydrochloride with N-2-propyl hydroxylamine hydrochloride. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With sodium hydroxide; In diethyl ether; water; | EXAMPLE 2 4,4'-Methylenebis(1-hydroxy-1-isopropyl-3-phenylurea) STR17 The same general procedure as reported in Example 1 was followed. 4,4'-Methylenebis(phenylisocyanate) (2.0 g, 8 mmol), N-isopropylhydroxylamine-hydrochloride (2.7 g, 24 mmol), NaOH (1.1 g dissolved in 10 ml of water), diethyl ether (100 ml), and water (5 ml) were combined. Filtration of the reaction mixture yielded 2.9 g of the desired product as a white powder. Recrystallization from N,N-dimethylformamide.backslash.water provided an analytically pure sample: MP: 219.0 C. (decomp); 1 H NMR (300 MHz, DMSO): delta 9.24 (s, 2H), 8.82 (s, 2H), 7.50 (d, J=8.5 Hz, 4H), 7.06 (d, J=8.5 Hz, 4H), 4.30 (septet, J=6.6 Hz, 2H), 3.78 (s, 2H) 1.06 (d, J=6.6 Hz, 12H); 13 C NMR (75 MHz, DMSO): delta 156.9, 136.7, 134.7, 127.8, 118.7, 47.9, 39.4, 18.1; MS (FAB): m/e 401.2189 (401.2189 calc'd for C21 H29 N4 O4, M+H); Anal. calc'd for C21 H28 N4 O4: C, 62.98; H, 7.05; N, 13.99. Found: C, 63.04; H, 6.96; N, 13.85. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With thionyl chloride; sodium hydrogencarbonate; In dichloromethane; water; | EXAMPLE 287 5-Chloro-N-hydroxy-N-(1-methylethyl)-3-(trimethylsilyl)-2-thiophenecarboxamide 5-Chloro-3-(trimethylsilyl)-2-thiophenecarboxylic acid chloride was prepared by the reaction of 1 g 5-chloro-3-(trimethylsilyl)-2-thiophenecarboxylic acid (prepared as in Example 263) and 6 mL thionyl chloride, using the procedure of step a in Example 248. This product was dissolved in CH2 Cl2 at 0 C. and added to a mixture of <strong>[50632-53-6]N-<strong>[50632-53-6]isopropylhydroxylamine hydrochloride</strong></strong> (0.55 g, 5 mmol) and 4 g NaHCO3 in 20 mL CH2 Cl2 and 20 mL water. The resulting reaction mixture was stirred at RT for additional 3 h. The organic layer was separated, washed with brine, dried and concentrated. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With hydrogenchloride; In tetrahydrofuran; pyridine; dichloromethane; water; | EXAMPLE 13 3-(6,11-Dihydro-11-oxodibenz[b,e]oxepin-2-yl)-N-hydroxy-N-(1-methylethyl)propanamide A stirring solution of 11.58 g of <strong>[50632-53-6]N-<strong>[50632-53-6]isopropylhydroxylamine hydrochloride</strong></strong> in 300 ml of dry pyridine was chilled, degassed using several vacuum/N2 cycles, and treated dropwise over several minutes with a solution of 7.54 g of 3-(6,11-dihydro-11-oxodibenz[b,e]oxepin-2-yl)propanyl chloride in 200 ml of dry tetrahydrofuran. The solution was allowed to equilibrate to room temperature overnight. The reaction was quenched with 200 ml of water, concentrated in vacuo to remove solvents, and partitioned against a total of 300 ml of methylene chloride and 400 ml of 10% hydrochloric acid (pH of the resulting aqueous phase was below 1). The organic phase was washed with 500 ml of water, dried (Na2 SO4), and concentrated to an oil in vacuo. Thin layer analysis indicated a mixture that was separated via HPLC to give 3.78 g of an oil, which crystallized upon standing at room temperature. The purified solids were recrystallized from acetone/cyclohexene to give 2.50 g of 3-(6,11-dihydro-1-oxo-dibenz[b,e]oxepin-2-yl)-N-hydroxy-N-(1-methylethyl)propanamide, m.p. 117.5-118 C. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With sodium hydroxide; In dichloromethane; water; | Step A: Dihydro-4-Bromo-2-Isopropyl-2H-1,2-Oxazin-3(4H)-One To a stirred mixture of 5.3 g (47 mmol) of <strong>[50632-53-6]N-<strong>[50632-53-6]isopropylhydroxylamine hydrochloride</strong></strong> in 100 ml of methylene chloride cooled to 5 C. was added 3.8 g (47 mmol) of 50% sodium hydroxide solution in 20 ml of water. To this mixture was added with stirring 12.4 g (47 mmol) of 2,4-dibromobutyrylchloride and twenty minutes later an additional 7.6 g (94 mmol) of 50% sodium hydroxide solution was added. After twenty hours the organic phase was separated, dried over anhydrous magnesium sulfate and concentrated to an oil. This oil was chromatographed on silica gel with 40% ethyl acetate-hexane to afford 1.1 g of oily dihydro-4-bromo-2-isopropyl-2H-1,2-oxazin-3(4H)-one. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
4.2 g (54%) | With hydrogenchloride; In (2S)-N-methyl-1-phenylpropan-2-amine hydrate; ethanol; | EXAMPLE 8 5-[[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-2-[hydroxy(1-methylethyl)amino]-4(5H)-thiazolone, (Z)- A mixture of <strong>[50632-53-6]N-<strong>[50632-53-6]isopropylhydroxylamine hydrochloride</strong></strong> (5.5 g, 0.049 mole), potassium-t-butoxide (4.83 g, 0.043 mole), and ethanol (500 mL) is stirred at room temperature for 15 minutes. 5-[(3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene]-2-(methylthio)-4(5H)-thiazolone (7.27 g, 0.02 mole) is then added and the mixture is refluxed with stirring for six hours. After removal of the solvent under reduced pressure, the cooled reaction mixture is poured into a mixture of ice-water containing 1N hydrochloric acid and extracted with ether. The organic layer is washed with water, dried, and the solvent is evaporated to give 7.7 g of a residue. The residue is flash chromatographed on silica gel (202 g), eluding first with methylene chloride and then with methylene chloride-methanol (9:1) to give 7.0 g purified product. It is recrystallized from methylene chloride-ethyl acetate-ether to give 4.2 g (54%) of pure 5-[[3,5-Bis-(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-2-[hydroxy(1-methylethyl)amino]-4(5H)-thiazolidinone, (Z)-, mp 208 C. (dec). Anal. for C21 H30 N2 O3 S: Calcd: C, 64.58; H, 7.74; N, 7.17. Found: C, 64.52; H, 7.67; N, 6.92. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
To a stirred solution of [(R/S)-2-METHYL-3-({4-[(2-METHYLQUINOLIN-4-YL) METHOXY] PIPERIDIN-1-] [YL} SULPHONYL)] propionic acid (125mg) (described within Example 12) in DCM (4ml) under argon was added DMF (0. [03ML).] The solution was cooled to [0XB0;C] and oxalyl chloride (0. [36ML)] was added in a dropwise manner. The temperature was maintained at [0XB0;C] for 45 minutes and the solution then concentrated in vacuo and dried under vacuum for ten minutes. The resulting brown gum was dissolved in DCM [(2ML)] and added to a vigorously stirred solution of <strong>[50632-53-6]N-<strong>[50632-53-6]isopropylhydroxylamine hydrochloride</strong></strong> (173mg) and triethylamine (0. [22ML)] in THF [(5ML)] dropwise over 2 minutes. Stirring was continued for Ihour after which the reaction mixture was diluted with EtOAc [(20ML)] and treated with saturated sodium chloride [(LOML),] dried (sodium sulphate), concentrated in vacuo and purified on a lOg silica bond elute using a 0-5% EtOH/DCM gradient over 40 minutes as eluent to give (R/S)-N-hydroxy-N-isopropyl-2- [METHYL-3- ( {4- [] (2-methylquinolin-4-yl) methoxy] [PIPERIDIN-1-YL LSULPHONYL) PROPANAMIDE AS] a pale yellow foam (43mg). NMR : [8 1.] 05 (d, 6H), 1.15 (d, 3H), 1.7 (m, 2H), 1.95 (m, 2H), 2.65 (s, 3H), 2.9 (m, 1H), 3.0 (m, 2H), 3.4 (m, 4H + [HA0),] 3.7 (m, 1H), 4.5 (m, 1H), 5.0 (s, 2H), 7.4 (s, 1H), 7.5 (t, 1H), 7.7 (t, [1H),] 7.9 (d, 1H), 8. 05 (d, 1H), 9.4 (s, 1H) ; MS: 464. 28. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With triethylamine; In dichloromethane; at 20℃; for 24h; | To a solution of triphosgene (49 mg, 0.17 mmol) in dichloromethane (5.0 ml) was added 4-(4,5-bis(4-methoxyphenyl)oxazol-2-yl)piperidine (Reference Example 78) (182 mg, 0.50 mmol) and triethylamine (101 mg, 1.00 mmol) at -78C, and the mixture was gradually heated to room temperature. Distilled water was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was dried over magnesium sulfate and then concentrated under a reduced pressure. The residue was dissolved with the addition of dichloromethane (5.0 ml), <strong>[50632-53-6]N-<strong>[50632-53-6]isopropylhydroxylamine hydrochloride</strong></strong> (58 mg, 0.52 mmol) and triethylamine (105 mg, 1.03 mmol) were added thereto, and the mixture was stirred at room temperature for 24 hours. An aqueous solution of saturated ammonium chloride was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was dried over sodium sulfate and concentrated under a reduced pressure. The residue was purified by flash chromatography (amine silica gel, n-hexane/ethyl acetate) to give a title compound (141 mg, 0.30 mmol, 61%) as a colorless amorphous product. 1H-NMR (400 MHz, CDCl3) delta: 1.18 (6H, d, J = 6.6 Hz), 1.91-2.01 (2H, m), 2.14-2.18 (2H, m), 3.09-3.17 (3H, m), 3.49-3.56 (1H, m), 3.83 (3H, s), 3.83 (3H, s), 4.01-4.06 (2H, m), 6.36 (1H, s), 6.87-6.91 (4H, m), 7.48 (2H, d, J = 8.0 Hz), 7.55 (2H, d, J = 8.0 Hz). IR (KBr, cm-1): 3376, 2932, 1613, 1520, 1500, 1441, 1364, 1298, 1251, 1176, 1032, 834. EI-MS: m/z = 465 (M+). HR-MS (EI): measured value: 465.2264, calculated value: (C26H31N3O5), 465.2264. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With triethylamine; In tetrahydrofuran; at 50℃; for 5h; | To a solution of 4-(4,5-bis(4-methoxyphenyl)thiazol-2-yl)piperidine (Reference Example 93) (201 mg, 0.528 mmol) in tetrahydrofuran (15 ml) was added triphosgene (65 mg, 0.22 mmol) and triethylamine (100 mul, 0.73 mmol) at 0C, and the mixture was stirred at the same temperature for hours. <strong>[50632-53-6]N-<strong>[50632-53-6]isopropylhydroxylamine hydrochloride</strong></strong> (82 mg, 0.74 mmol) and triethylamine (200 mul, 1.5 mmol) were added to the reaction solution, the mixture was stirred at 50C for 5 hours, and the resultant was then cooled to room temperature. The reaction solution was concentrated under a reduced pressure, and distilled water was added to the residue, followed by extraction with ethyl acetate. The organic layer was dried over magnesium sulfate and concentrated under a reduced pressure. The residue was purified by flash chromatography (amine silica gel, n-hexane/ethyl acetate) to give a title compound (145 mg, 0.301 mmol, 57%) as a white amorphous product. 1H-NMR (400 MHz, CDCl3) delta: 1.19 (6H, d, J = 6.6 Hz), 1.81-1.92 (2H, m), 2.17-2.25 (2H, m), 3.03-3.13 (2H, m), 3.48-3.56 (1H, m), 3.80 (3H, s), 3.82 (3H, s), 4.09-4.17 (2H, m), 6.33 (1H, s), 6.82 (2H, d, J = 8.8 Hz), 6.85 (2H, d, J = 8.8 Hz), 7.25 (2H, d, J = 8.8 Hz), 7.44 (2H, d, J = 8.8 Hz). IR (KBr, cm-1): 3266, 1651, 1608, 1515, 1496, 1441, 1294, 1249, 1176. |
Tags: 50632-53-6 synthesis path| 50632-53-6 SDS| 50632-53-6 COA| 50632-53-6 purity| 50632-53-6 application| 50632-53-6 NMR| 50632-53-6 COA| 50632-53-6 structure
[ 57497-39-9 ]
N-(tert-Butyl) hydroxylamine hydrochloride
Similarity: 0.87
[ 42548-78-7 ]
N-Ethylhydroxylamine hydrochloride
Similarity: 0.77
[ 253605-31-1 ]
N-(tert-Butyl)hydroxylamine acetate
Similarity: 0.57
[ 4229-44-1 ]
N-Methylhydroxylamine hydrochloride
Similarity: 0.54
[ 57497-39-9 ]
N-(tert-Butyl) hydroxylamine hydrochloride
Similarity: 0.87
[ 42548-78-7 ]
N-Ethylhydroxylamine hydrochloride
Similarity: 0.77
[ 25100-12-3 ]
N-Cyclohexylhydroxylamine hydrochloride
Similarity: 0.65
[ 57497-39-9 ]
N-(tert-Butyl) hydroxylamine hydrochloride
Similarity: 0.87
[ 42548-78-7 ]
N-Ethylhydroxylamine hydrochloride
Similarity: 0.77
[ 25100-12-3 ]
N-Cyclohexylhydroxylamine hydrochloride
Similarity: 0.65
[ 253605-31-1 ]
N-(tert-Butyl)hydroxylamine acetate
Similarity: 0.57
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :